Autopsy report · NCT04218019

Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation

“Organizational reasons”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

Juergen Debus

Sponsor type

University, hospital or other

Conditions

Newly Diagnosed Glioblastoma in Patients ≥70 Years

Interventions

TTFields

Participants

0

Sites

1

Countries

Germany

Trials that died the same way

• A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)
  “Business Reasons” (85% match in meaning)
• The Effect of Sodium Bicarbonate (Nephrotrans®) on Calcification Propensity of Serum in Kidney Transplant Recipients
  “due to organizational reason” (84% match in meaning)
• PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin
  “Business reason” (78% match in meaning)
• A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer
  “Administrative reasons” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.